In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £159.55. The company’s shares opened today at p10,484.00.
According to TipRanks, Sharma is an analyst with an average return of -1.3% and a 40.74% success rate. Sharma covers the Healthcare sector, focusing on stocks such as Halozyme, Innate Pharma SA, and Autolus Therapeutics.
In addition to Goldman Sachs, AstraZeneca also received a Buy from Barclays’s Emily Field in a report issued today. However, on November 20, UBS upgraded AstraZeneca (LSE: AZN) to a Hold.
AZN market cap is currently £162.4B and has a P/E ratio of 31.71.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
AstraZeneca (AZN) Company Description:
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read More on GB:AZN:
